NetworkNewsBreaks – Lexaria Bioscience Corp.’s
Post# of 421
(Total Views: 268)
Posted On: 09/03/2021 3:44:18 PM
NetworkNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Proprietary Technology Elevating Quantity of Drugs Delivered Across Blood-Brain Barrier by 1,900%
Lexaria Bioscience Corp. (NASDAQ: LEXX) recently announced that a tolerability and pharmacokinetic study, performed by an independent, premier animal testing laboratory in the U.S., had demonstrated that administration of colchicine using its proprietary DehydraTECH(TM) resulted in increased delivery. “Colchicine is an approved therapeutic with anti-inflammatory effects primarily used to treat gout and cardiac conditions such as pericarditis. It was the latest of several drugs Lexaria tested with known SARS-CoV-2/COVID-19 antiviral properties after it showed potent effects in mitigating the cytokine storm associated with the virus. Additionally, colchicine is occasionally used to treat emergent pericarditis in children, which would make the substance potentially beneficial against this form of cardiac inflammation when it occurs as a side effect of mRNA COVID-19 vaccines,” reads a recent article. As colchicine has a marginal difference between toxic and non-toxic doses, Lexaria hopes that by using DehydraTECH, it can improve the drug’s bioavailability beyond current levels of approximately 45%, which would potentially allow lower dosing requirements. “Lexaria’s DehydraTECH promotes fast-acting, less expensive and more effective oral drug delivery. The method has been evaluated thoroughly through in vivo, in vitro and human clinical testing. The company has shown, through animal studies, that DehydraTECH technology elevates the quantity of drugs delivered across the blood-brain barrier by as much as 1,900%. The research has initiated new patent applications and opened the possibilities for improved drug delivery.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Lexaria Bioscience Corp. (NASDAQ: LEXX) recently announced that a tolerability and pharmacokinetic study, performed by an independent, premier animal testing laboratory in the U.S., had demonstrated that administration of colchicine using its proprietary DehydraTECH(TM) resulted in increased delivery. “Colchicine is an approved therapeutic with anti-inflammatory effects primarily used to treat gout and cardiac conditions such as pericarditis. It was the latest of several drugs Lexaria tested with known SARS-CoV-2/COVID-19 antiviral properties after it showed potent effects in mitigating the cytokine storm associated with the virus. Additionally, colchicine is occasionally used to treat emergent pericarditis in children, which would make the substance potentially beneficial against this form of cardiac inflammation when it occurs as a side effect of mRNA COVID-19 vaccines,” reads a recent article. As colchicine has a marginal difference between toxic and non-toxic doses, Lexaria hopes that by using DehydraTECH, it can improve the drug’s bioavailability beyond current levels of approximately 45%, which would potentially allow lower dosing requirements. “Lexaria’s DehydraTECH promotes fast-acting, less expensive and more effective oral drug delivery. The method has been evaluated thoroughly through in vivo, in vitro and human clinical testing. The company has shown, through animal studies, that DehydraTECH technology elevates the quantity of drugs delivered across the blood-brain barrier by as much as 1,900%. The research has initiated new patent applications and opened the possibilities for improved drug delivery.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)